Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnAISquareMore
G City tender offer lifts Citycon stake to 89.66% in preliminary results

G City tender offer lifts Citycon stake to 89.66% in preliminary results

ReutersReuters2026/08/04 16:30
  • G City’s cash tender offer for remaining Citycon shares drew 5,159,902 shares, about 2.8% of shares and voting rights.
  • Including existing holdings, G City and its unit Gazit Europe Netherlands would hold 164,588,556 shares, about 89.66% of Citycon.
  • The offer period ran from July 6 to Aug. 3; final results are due on or about Aug. 5.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Citycon Oyj published the original content used to generate this news brief via Cision (Ref. ID: 20260804:BIT:4279:0) on August 04, 2026, and is solely responsible for the information contained therein.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Competition in US oral weight-loss drugs intensifies! Eli Lilly (LLY.US) Foundayo captures 30% of new patients, narrowing Novo Nordisk's (NVO.US) first-mover advantage

Eli Lilly stated on Monday that its oral weight-loss drug, Foundayo, has captured over 30% of the market share among new patients in the US oral obesity treatment market, narrowing the early lead achieved by Danish competitor Novo Nordisk with its Wegovy oral tablets.

智通财经2026/09/15 03:21
Competition in US oral weight-loss drugs intensifies! Eli Lilly (LLY.US) Foundayo captures 30% of new patients, narrowing Novo Nordisk's (NVO.US) first-mover advantage